Posted previously on this
Following up with a new post as it is nearing catalysts and technicals have suggested that it has broke out of a long consolidation period
I personally think this is due for a major run where the March earnings call should bring a lot of positivity to this stock. I'll be expecting encouraging first quarter sales of Olinvyk, their FDA approved drug that could potentially replace morphine and address opioid shortage. TRVN is also expected to report on their top-line data for another drug TRV027 this quarter.
www.genengnews.com/c...ates/trevena-trv027/
4 months price target: $7
Long term price target: TBD
Following up with a new post as it is nearing catalysts and technicals have suggested that it has broke out of a long consolidation period
I personally think this is due for a major run where the March earnings call should bring a lot of positivity to this stock. I'll be expecting encouraging first quarter sales of Olinvyk, their FDA approved drug that could potentially replace morphine and address opioid shortage. TRVN is also expected to report on their top-line data for another drug TRV027 this quarter.
www.genengnews.com/c...ates/trevena-trv027/
4 months price target: $7
Long term price target: TBD
코멘트:
Dropped a significant amount since my post but overall market is seeing red too. Will be holding this through their earnings
액티브 트레이드:
Been averaging down on this